Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Sweden.
Nat Rev Endocrinol. 2013 Feb;9(2):72-4. doi: 10.1038/nrendo.2012.252. Epub 2013 Jan 8.
Researchers are trying to develop more efficient and safer antifracture treatments. Besides the ongoing promising clinical trials involving antibodies to the Wnt antagonist sclerostin or inhibition of the osteoclast enzyme cathepsin K, the year 2012 has seen several novel osteoporosis targets identified by using different methodological approaches.
研究人员正在努力开发更有效和更安全的抗骨折治疗方法。除了正在进行的涉及抗 Wnt 拮抗剂硬骨素抗体或抑制破骨细胞酶组织蛋白酶 K 的有前途的临床试验外，2012 年还使用不同的方法学方法确定了几个新的骨质疏松靶点。
